ATE421571T1 - Neues protein tab2 - Google Patents
Neues protein tab2Info
- Publication number
- ATE421571T1 ATE421571T1 AT99974205T AT99974205T ATE421571T1 AT E421571 T1 ATE421571 T1 AT E421571T1 AT 99974205 T AT99974205 T AT 99974205T AT 99974205 T AT99974205 T AT 99974205T AT E421571 T1 ATE421571 T1 AT E421571T1
- Authority
- AT
- Austria
- Prior art keywords
- tab2
- signal transduction
- new protein
- tak1
- activation
- Prior art date
Links
- 101000674728 Homo sapiens TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 Proteins 0.000 title abstract 6
- 102100021227 TGF-beta-activated kinase 1 and MAP3K7-binding protein 2 Human genes 0.000 title abstract 6
- 230000019491 signal transduction Effects 0.000 abstract 4
- 108010002352 Interleukin-1 Proteins 0.000 abstract 3
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 108091008743 testicular receptors 4 Proteins 0.000 abstract 2
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 abstract 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007076 release of cytoplasmic sequestered NF-kappaB Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP1999/006466 WO2001038527A1 (en) | 1999-11-19 | 1999-11-19 | Novel protein tab2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE421571T1 true ATE421571T1 (de) | 2009-02-15 |
Family
ID=14237333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99974205T ATE421571T1 (de) | 1999-11-19 | 1999-11-19 | Neues protein tab2 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7153664B2 (de) |
| EP (1) | EP1234880B9 (de) |
| JP (1) | JP4488665B2 (de) |
| AT (1) | ATE421571T1 (de) |
| DE (1) | DE69940359D1 (de) |
| WO (1) | WO2001038527A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE421571T1 (de) | 1999-11-19 | 2009-02-15 | Kunihiro Matsumoto | Neues protein tab2 |
| WO2004022599A1 (ja) * | 2002-08-22 | 2004-03-18 | Peptide Door Co.,Ltd. | 融合抗体及びその作成方法 |
| GB0306071D0 (en) * | 2003-03-17 | 2003-04-23 | Novartis Ag | Organic compounds |
| EP1608755B1 (de) * | 2003-04-01 | 2012-10-17 | Helmholtz-Zentrum für Infektionsforschung GmbH | Tak1-vermittelte hemmung der osteogenese |
| US8765370B2 (en) * | 2009-06-11 | 2014-07-01 | Scinopharm Taiwan, Ltd | Inhibition-based high-throughput screen strategy for cell clones |
| KR101595318B1 (ko) | 2014-03-25 | 2016-02-18 | 한국알프스 주식회사 | 다채널 led 조명기구에서 채널간의 전류편차 최소화 제어방법 |
| WO2016011155A1 (en) | 2014-07-15 | 2016-01-21 | Kapre Subhash V | Genetically detoxified pertussis that maintains intrinsic adjuvant activity |
| CN110201418B (zh) * | 2019-05-09 | 2020-10-27 | 西安交通大学 | 一种基于固定化SNAP-tag融合蛋白的细胞膜色谱柱及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837703A (en) * | 1993-03-31 | 1998-11-17 | Cell Therapeutics, Inc. | Amino-alcohol substituted cyclic compounds |
| US5576423A (en) * | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
| JP3907247B2 (ja) | 1996-04-24 | 2007-04-18 | 中外製薬株式会社 | Tab1蛋白質及びそれをコードするdna |
| ATE283356T1 (de) | 1996-04-24 | 2004-12-15 | Chugai Pharmaceutical Co Ltd | Tab1 protein und dafür kodierende dna |
| ATE421571T1 (de) | 1999-11-19 | 2009-02-15 | Kunihiro Matsumoto | Neues protein tab2 |
-
1999
- 1999-11-19 AT AT99974205T patent/ATE421571T1/de not_active IP Right Cessation
- 1999-11-19 DE DE69940359T patent/DE69940359D1/de not_active Expired - Lifetime
- 1999-11-19 JP JP2001539870A patent/JP4488665B2/ja not_active Expired - Fee Related
- 1999-11-19 WO PCT/JP1999/006466 patent/WO2001038527A1/ja not_active Ceased
- 1999-11-19 EP EP99974205A patent/EP1234880B9/de not_active Expired - Lifetime
-
2002
- 2002-05-20 US US10/151,569 patent/US7153664B2/en not_active Expired - Fee Related
-
2006
- 2006-12-04 US US11/633,653 patent/US8058241B2/en not_active Expired - Fee Related
-
2011
- 2011-10-21 US US13/278,850 patent/US8491900B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20120064084A1 (en) | 2012-03-15 |
| US20030040050A1 (en) | 2003-02-27 |
| US20070161565A1 (en) | 2007-07-12 |
| US7153664B2 (en) | 2006-12-26 |
| DE69940359D1 (de) | 2009-03-12 |
| JP4488665B2 (ja) | 2010-06-23 |
| WO2001038527A1 (en) | 2001-05-31 |
| EP1234880B9 (de) | 2009-09-23 |
| EP1234880A4 (de) | 2004-03-31 |
| US8058241B2 (en) | 2011-11-15 |
| EP1234880A1 (de) | 2002-08-28 |
| EP1234880B1 (de) | 2009-01-21 |
| US8491900B2 (en) | 2013-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE421571T1 (de) | Neues protein tab2 | |
| DE69917469D1 (de) | Pyrimidin derivate | |
| BRPI0415433A (pt) | derivados de n-[fenil (alquilpiperidin-2-il)metil] benzamida, seu preparo e sua aplicação em terapêutica | |
| DZ3420A1 (fr) | Combinaison d'herbicides avec des sulfonylurees speciales | |
| WO1999067252A3 (en) | Epothilone derivatives and their synthesis and use | |
| HK1046687A1 (zh) | 喹唑啉衍生物 | |
| DK1109812T3 (da) | Pyrrolobenzodiazepiner | |
| EP1288202A4 (de) | N-acyltetrahydroisochinolin-derivate | |
| ATE442364T1 (de) | Kristalline form von linezolid | |
| DE69226057D1 (de) | Elektroakustischer Wandler vom Elektret-Typ | |
| DK482088A (da) | Anvendelse af 1,3,7-trisubstituerede purin-2,6-dion-forbindelser til fremstilling af et laegemiddel med interleukin-1-inhiberende virkning | |
| DE60100393D1 (de) | Drehwinkelsensor mit linearer Ausgangscharakteristik | |
| DK1258167T3 (da) | Akustisk transducer med forbedret akustisk dæmper | |
| BR0307071A (pt) | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico | |
| FI935944A0 (fi) | Pyratsolopyrimidin- samt pyrimidinylbisfosfonestrar som anti- inflammatorer | |
| DE69609576D1 (de) | Bioverfügbare kristalline Form des Cefuroxim-Axetils | |
| DE60141875D1 (de) | Messung des Ähnlichkeitsgrads der Stimme | |
| DK0747392T3 (da) | Dobbeltvirkende inhibitorer indeholdende 1,2-diazepiner | |
| KR950704250A (ko) | 소염제 및 항변성제로서의 신규한 치환된 아제티디논(New substituted azetidinones as anti―inflammatory and antidegenerative agents) | |
| FI914855L (fi) | Ekstrudoitavan eteeni-hydroksiakrylaatti-sekapolymeerin käyttö | |
| DE69024727D1 (de) | Kornverfeinerung des Zirkoniums mittels Silizium | |
| EP1632484A4 (de) | Thiadiazolinderivat | |
| LV10448A (lv) | Piperazinilkamparsulfoniloksitocina antagonista aizvietotie amidu atvasinajumi | |
| HRP20090180T1 (en) | Biotinylated hexadecasaccharides, pharmaceutical compositions and use thereof | |
| WO2001002366A3 (en) | Substituted isoquinoline derivatives and their use as inticonvulsants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |